Credit Suisse upgraded Medtronic (NYSE: MDT ) from Neutral to Outperform and raised the price target from $47.00 to $50.00. Credit Suisse noted, "MDT's F2H13 & F14 growth aspirations indicate increased confidence that the last 2 quarters of ~5% WW CC growth represent sustainable improvement relative to the flattish top-line